CMPX
Compass Therapeutics, Inc.
Key Financials
Net Income
$-66489000
↓ 34.7%
Operating Income
$-72839000
↓ 28.6%
Total Liabilities
$22.8M
↑ 50.3%
Total Assets
$219.6M
↑ 56.4%
Cash & Equivalents
$30.6M
↓ 29.5%
Shareholders' Equity
$196.8M
↑ 57.1%
Long-term Debt
$0.00
↓ 100.0%
Operating Cash Flow
$-49143000.00
↓ 9.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-8 | 3/12/2026 | View on SEC |
| 10-K | 3/5/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
| SCHEDULE 13G/A | 2/13/2026 | View on SEC |
| 4 | 2/10/2026 | View on SEC |
| SCHEDULE 13G | 1/21/2026 | View on SEC |
| 4 | 1/12/2026 | View on SEC |
| EFFECT | 1/7/2026 | View on SEC |
| 8-K | 1/6/2026 | View on SEC |
| 4 | 1/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CMPX |
| Company Name | Compass Therapeutics, Inc. |
| CIK | 1738021 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-500-8099 |